Growth hormone (GH) responses to GH-releasing peptide and to GH-releasing hormone in GH-deficient children
Author
dc.contributor.author
Mericq, Verónica
Author
dc.contributor.author
Cassorla Goluboff, Fernando
Author
dc.contributor.author
Garcia, Hernan
Author
dc.contributor.author
Avila, Alejandra
Author
dc.contributor.author
Bowers, Cyril Y.
Author
dc.contributor.author
Merriam, George R.
Admission date
dc.date.accessioned
2019-01-29T14:55:16Z
Available date
dc.date.available
2019-01-29T14:55:16Z
Publication date
dc.date.issued
1995
Cita de ítem
dc.identifier.citation
Journal of Clinical Endocrinology and Metabolism, Volumen 80, Issue 5, 2018, Pages 1681-1684
Identifier
dc.identifier.issn
19457197
Identifier
dc.identifier.issn
0021972X
Identifier
dc.identifier.other
10.1210/jcem.80.5.7745018
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/161320
Abstract
dc.description.abstract
The GH-releasing peptides (GHRPs) are a family of hexa- and heptapeptides that specifically stimulate GH secretion in normal adults and children. They would be an attractive potential form of therapy for GH deficiency (GHD) if they are also active in these patients. Their action, however, appears to result at least in part through hypothalamic responses, which may be impaired in GHD, and their ability to evoke a GH response in these patients must therefore be directly examined. We studied GH responses to the heptapeptide GHRP-1 in 22 prepubertal children with previously documented GHD and growth failure and compared them to responses to GHRH and the two peptides administered together. Patients received 1 μg/kg GHRH-(1–44)NH2, 1 μg/kg GHRP-1, or both, in random order. Tests were separated by at least 1 week. GHRP-1 evoked a significant GH response in 60% of the patients, comparable to the 68% who responded to GHRH. The magnitudes of the peak responses were similar (7.5 ± 8.0 μg/L to GHR